Generic Name: tofacitinib
Brand Name: Xeljanz
Manufacturer: Pfizer Canada Inc.
Indications: Arthritis, Psoriatic
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with active psoriatic arthritis (PsA) when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.
Submission Type: New Indication
Project Status: Pending
Call For Patient Input: June 12, 2018
Patient Input Closed: August 1, 2018
Anticipated Date: July 11, 2018
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
arthritis, dermatology, musculoskeletal